|
英文药名: Regranex(becaplermin gel) 中文药名: 贝卡普勒明凝胶 生产厂家：Smith & Nephew, Inc.
Gel: 0.01% (3) CONTRAINDICATIONS Known neoplasm(s) at the site(s) of application (4) WARNINGS AND PRECAUTIONS Malignancies distant from the site of application have been reported in both a clinical study and in postmarketing use. REGRANEX Gel should be used with caution in patients with a known malignancy. (5.1) ADVERSE REACTIONS Erythematous rashes occurred in 2% of patients treated with REGRANEX Gel (6.1) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch, or Smith & Nephew, Inc. at 1-800-441-8227. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 8/2014 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Indication REGRANEX (becaplermin) Gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. 1.2 Limitations of Use The efficacy of REGRANEX Gel has not been established for the treatment of pressure ulcers and venous stasis ulcers [see Clinical Studies (14)] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue (Stage I or II, IAET staging classification) or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans. [see Nonclinical Toxicology (13.2)] REGRANEX Gel is a non-sterile, low bioburden preserved product. Therefore, it should not be used in wounds that close by primary intention. 2 DOSAGE AND ADMINISTRATION For topical use; not for oral, ophthalmic or intravaginal use. The amount of REGRANEX Gel to be applied will vary depending upon the size of the ulcer area. To calculate the length of gel to apply to the ulcer, measure the greatest length of the ulcer by the greatest width of the ulcer in either inches or centimeters. To calculate the length of gel in inches, use the formula shown below in Table 1, and to calculate the length of gel in centimeters, use the formula shown below in Table 2. Table 1: Formula to Calculate Length of Gel in Inches to Be Applied Daily
Table 2: Formula to Calculate Length of Gel in Centimeters to Be Applied Daily
The amount of REGRANEX Gel to be applied should be recalculated by the physician or wound caregiver at weekly or biweekly intervals depending on the rate of change in ulcer area. The weight of REGRANEX Gel from 15g tubes is 0.65g per inch length and 0.25g per centimeter length. To apply REGRANEX Gel, the calculated length of gel should be squeezed on to a clean measuring surface, e.g., wax paper. The measured REGRANEX Gel is transferred from the clean measuring surface using an application aid and then spread over the entire ulcer area to yield a thin continuous layer of approximately 1/16 of an inch thickness. The site(s) of application should then be covered by a saline moistened dressing and left in place for approximately 12 hours. The dressing should then be removed and the ulcer rinsed with saline or water to remove residual gel and covered again with a second moist dressing (without REGRANEX Gel) for the remainder of the day. REGRANEX Gel should be applied once daily to the ulcer until complete healing has occurred. If the ulcer does not decrease in size by approximately 30% after 10 weeks of treatment or complete healing has not occurred in 20 weeks, continued treatment with REGRANEX Gel should be reassessed. The step-by-step instructions for applying REGRANEX Gel for home administration are described under "Patient Counseling Information". [see Patient Counseling Information (17)] 3 DOSAGE FORMS AND STRENGTHS Gel: 0.01%; clear, colorless to straw-colored gel 4 CONTRAINDICATIONS REGRANEX Gel is contraindicated in patients with known neoplasm(s) at the site(s) of application. 5 WARNINGS AND PRECAUTIONS 5.1 Cancer and Cancer Mortality REGRANEX Gel contains becaplermin, a recombinant human platelet-derived growth factor, which promotes cellular proliferation and angiogenesis. [see Clinical Pharmacology (12.1)] The benefits and risks of becaplermin treatment should be carefully evaluated before prescribing. Becaplermin should be used with caution in patients with a known malignancy. Malignancies distant from the site of application have occurred in becaplermin users in both a clinical study and postmarketing use, and an increased rate of death from systemic malignancies was seen in patients who have received 3 or more tubes of REGRANEX Gel. In a follow-up study, 491 (75%) of 651 subjects from two randomized, controlled trials of becaplermin gel 0.01% were followed for a median of approximately 20 months to identify malignancies diagnosed after the end of the trials. Eight of 291 subjects (3%) from the becaplermin group and two of 200 subjects (1%) from the vehicle/standard of care group were diagnosed with cancers during the follow-up period, a relative risk of 2.7 (95% confidence interval 0.6–12.8). The types of cancers varied and all were remote from the treatment site. In a retrospective study of a medical claims database, cancer rates and overall cancer mortality were compared between 1,622 patients who used REGRANEX Gel and 2,809 matched comparators. Estimates of the incidence rates reported below may be under-reported due to limited follow-up for each individual. The incidence rate for all cancers was 10.2 per 1,000 person years for patients treated with REGRANEX Gel and 9.1 per 1,000 person years for the comparators. Adjusted for several possible confounders, the rate ratio was 1.2 (95% confidence interval 0.7–1.9). Types of cancers varied and were remote from the site of treatment. The incidence rate for mortality from all cancers was 1.6 per 1,000 person years for those who received REGRANEX Gel and 0.9 per 1,000 person years for the comparators. The adjusted rate ratio was 1.8 (95% confidence interval 0.7–4.9). The incidence rate for mortality from all cancers among patients who received 3 or more tubes of REGRANEX Gel was 3.9 per 1,000 person years and 0.9 per 1,000 person years in the comparators. The adjusted rate ratio for cancer mortality among those who received 3 or more tubes relative to those who received none was 5.2 (95% confidence interval 1.6–17.6). [see Boxed Warning] 5.2 Application Site Reactions If application site reactions occur, the possibility of sensitization or irritation caused by parabens or m-cresol should be considered. Consider interruption or discontinuation and further evaluation (e.g. patch testing) as dictated by clinical circumstances. 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a follow-up study from two randomized, controlled trials, an increased rate of cancer remote from the becaplermin treatment site was observed in subjects treated with REGRANEX Gel. [see Warnings and Precautions (5.1)] In clinical trials, erythematous rashes occurred in 2% of patients treated with REGRANEX Gel (and good ulcer care) or placebo (and good ulcer care), and none in patients receiving good ulcer care alone. Patients treated with REGRANEX Gel did not develop neutralizing antibodies against becaplermin. 6.2 Postmarketing Experience An increased rate of mortality secondary to malignancy was observed in patients treated with 3 or more tubes of REGRANEX Gel in a postmarketing retrospective cohort study. [see Boxed Warning and Warnings and Precautions (5.1)] Burning sensation at the site of application and erythema have been reported during post-approval use of REGRANEX Gel. Because post approval adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the drug. 7 DRUG INTERACTIONS It is not known if REGRANEX Gel interacts with other topical medications applied to the ulcer site. The use of REGRANEX Gel with other topical drugs has not been studied. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women treated with REGRANEX Gel. REGRANEX Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal reproduction studies have not been conducted with REGRANEX Gel. 8.3 Nursing Mothers It is not known whether becaplermin is excreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when REGRANEX Gel is administered to nursing women. 8.4 Pediatric Use Safety and effectiveness of REGRANEX Gel in pediatric patients below the age of 16 years have not been established. 8.5 Geriatric Use Among patients receiving any dose of REGRANEX Gel in clinical studies of diabetic lower extremity ulcers, 150 patients were 65 years of age and older. No overall differences in safety or effectiveness were observed between patients < 65 years of age and patients ≥ 65 years of age. The number of patients aged 75 and older were insufficient (n=34) to determine whether they respond differently from younger patients. 10 OVERDOSAGE There are no data on the effects of becaplermin overdose. 11 DESCRIPTION REGRANEX Gel contains becaplermin, a recombinant human platelet-derived growth factor for topical administration. Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet-derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains that are bound together by disulfide bonds. REGRANEX Gel is a non-sterile, low bioburden, preserved, sodium carboxymethylcellulose-based (CMC) topical gel, containing the active ingredient becaplermin and the following inactive ingredients: carboxymethylcellulose sodium, glacial acetic acid, l-lysine hydrochloride, m-cresol, methylparaben, propylparaben, sodium acetate trihydrate, sodium chloride, and water for injection. Each gram of REGRANEX Gel contains 100 mcg of becaplermin. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action REGRANEX Gel has biological activity similar to that of endogenous platelet-derived growth factor, which includes promoting the chemotactic recruitment and proliferation of cells involved in wound repair and enhancing the formation of granulation tissue. 12.2 Pharmacodynamics Clinical pharmacodynamic studies have not been conducted. 12.3 Pharmacokinetics Ten patients with Stage III or IV (as defined in the International Association of Enterostomal Therapy (IAET) guide to chronic wound staging,1, 2 lower extremity diabetic ulcers received topical applications of becaplermin gel 0.01% at a dose range of 0.32–2.95 µg/kg (7µg/cm2) daily for 14 days. Six patients had non-quantifiable PDGF levels at baseline and throughout the study, two patients had PDGF levels at baseline which did not increase substantially, and two patients had PDGF levels that increased sporadically above their baseline values during the 14 day study period. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Becaplermin was not genotoxic in a battery of in vitro assays (including those for bacterial and mammalian cell point mutation, chromosomal aberration, and DNA damage/repair). Becaplermin was also not mutagenic in an in vivo assay for the induction of micronuclei in mouse bone marrow cells. Carcinogenesis and reproductive toxicity studies have not been conducted with REGRANEX Gel. 13.2 Animal Toxicology and/or Pharmacology In nonclinical studies, rats injected at the metatarsals with 3 or 10 mcg/site (approximately 60 or 200 mcg/kg) of becaplermin every other day for 13 days displayed histological changes indicative of accelerated bone remodeling consisting of periosteal hyperplasia and subperiosteal bone resorption and exostosis. The soft tissue adjacent to the injection site had fibroplasia with accompanying mononuclear cell infiltration reflective of the ability of PDGF to stimulate connective tissue growth. [see Indications and Usage (1.2)] 14 CLINICAL STUDIES The effects of REGRANEX Gel on the incidence of and time to complete healing in lower extremity diabetic ulcers were assessed in four randomized controlled studies. Of 922 patients studied, 478 received either REGRANEX Gel 0.003% or 0.01%. All study participants had lower extremity diabetic neuropathic ulcers that extended into the subcutaneous tissue or beyond (Stages III and IV of the IAET guide to chronic wound staging). Ninety-three percent of the patients enrolled in these four trials had foot ulcers. The remaining 7% of the patients had ankle or leg ulcers. The diabetic ulcers were of at least 8 weeks duration and had an adequate blood supply (defined as TcpO2 > 30 mm Hg). In the four trials, ninety-five percent of the ulcers measured in area up to 10 cm2, and the median ulcer size at baseline ranged from 1.4 cm2 to 3.5 cm2. All treatment groups received a program of good ulcer care consisting of initial complete sharp debridement, a non-weight-bearing regimen, systemic treatment for wound-related infection if present, moist saline dressings changed twice a day, and additional debridement as necessary. REGRANEX Gel 0.003% or 0.01% or placebo gel was applied once a day and covered with a saline moistened dressing. After approximately 12 hours, the gel was gently rinsed off and a saline moistened dressing was then applied for the remainder of the day. Patients were treated until complete healing, or for a period of up to 20 weeks. Patients were considered a treatment failure if their ulcer did not show an approximately 30% reduction in initial ulcer area after eight to ten weeks of REGRANEX Gel therapy. The primary endpoint, incidence of complete ulcer closure within 20 weeks, for all treatment arms is shown in Figure 1. In each study, REGRANEX Gel in conjunction with good ulcer care was compared to placebo gel plus good ulcer care or good ulcer care alone. In Study 1, a multicenter, double-blind, placebo controlled trial of 118 patients, the incidence of complete ulcer closure for REGRANEX Gel 0.003% (n=61) was 48% versus 25% for placebo gel (n=57; p=0.02, logistic regression analysis). In Study 2, a multicenter, double-blind, placebo controlled trial of 382 patients, the incidence of complete ulcer closure for REGRANEX Gel 0.01% (n=123) was 50% versus 36% for REGRANEX Gel 0.003% (n=132) and 35% for placebo gel (n=127). Only REGRANEX Gel 0.01% was significantly different from placebo gel (p=0.01, logistic regression analysis). The primary goal of Study 3, a multicenter controlled trial of 172 patients, was to assess the safety of vehicle gel (placebo; n=70) compared to good ulcer care alone (n=68). The study included a small (n=34) REGRANEX Gel 0.01% arm. Incidences of complete ulcer closure were 44% for REGRANEX Gel, 36% for placebo gel and 22% for good ulcer care alone. In Study 4, a multicenter, evaluator-blind, controlled trial of 250 patients, the incidences of complete ulcer closure in the REGRANEX Gel 0.01% arm (n=128) (36%) and good ulcer care alone (n=122) (32%) were not statistically different.
In a randomized, double-blind study of REGRANEX Gel (100 mcg/g once daily for 16 weeks) in patients with Stage III or IV pressure ulcers, the incidence of complete ulcer closure was 15% (28/189) in the becaplermin group and 12% (22/190) in the vehicle control group. This difference was not statistically significant. In two small, randomized, double-blinded studies of REGRANEX Gel (100 mcg/g once daily for 16 weeks) in patients with venous stasis ulcers, the combined incidence of complete ulcer closure was 46% (30/65) in the becaplermin group and 39% (26/67) in the vehicle control group. This difference was not statistically significant. 15 REFERENCES 1.J. Enterostomal Ther 15:4, 1988 2.Decubitis 2:24, 1989 16 HOW SUPPLIED/STORAGE AND HANDLING REGRANEX Gel is available in multi-use tubes in the following size: 15 g tube NDC 50484-810-15 REGRANEX Gel is for external use only. Store refrigerated at 2° – 8° C (36° – 46°F). Do not freeze. Do not use the gel after the expiration date shown at the bottom of the tube. 17 PATIENT COUNSELING INFORMATION [See FDA-approved patient labeling (Medication Guide)] Counsel patients to review and discuss any questions or concerns with their healthcare provider before starting REGRANEX and at regular intervals while receiving REGRANEX. Patients should be advised that: they should read the medication guide; hands should be washed thoroughly before applying REGRANEX Gel; the tip of the tube should not come into contact with the ulcer or any other surface; the tube should be recapped tightly after each use; a cotton swab, tongue depressor, or other application aid should be used to apply REGRANEX Gel; REGRANEX Gel should only be applied once a day in a carefully measured quantity [see Dosage and Administration (2)]. The measured quantity of gel should be spread evenly over the ulcerated area to yield a thin continuous layer of approximately 1/16 of an inch thickness. The measured length of the gel to be squeezed from the tube should be adjusted according to the size of the ulcer. The amount of REGRANEX Gel to be applied daily should be recalculated at weekly or biweekly intervals by the physician or wound care giver. Step-by-step instructions for application of REGRANEX Gel are as follows: Squeeze the calculated length of gel onto a clean, firm, nonabsorbable surface, e.g., wax paper. With a clean cotton swab, tongue depressor, or similar application aid, spread the measured REGRANEX Gel over the ulcer surface to obtain an even layer. Cover with a saline moistened gauze dressing. - after approximately 12 hours, the ulcer should be gently rinsed with saline or water toremove residual gel and covered with a saline-moistened gauze dressing (withoutREGRANEX Gel); - it is important to use REGRANEX Gel together with a good ulcer care program,including a strict non-weight-bearing program; - excess application of REGRANEX Gel has not been shown to be beneficial; - REGRANEX Gel should be stored in the refrigerator. Do not freeze REGRANEX Gel; - REGRANEX Gel should not be used after the expiration date on the bottom, crimpedend of the tube. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd2c7d21-7b07-4ab3-8983-816ab3223771 用于糖尿病性溃疡的贝卡普勒明(Regranex)对癌症患者禁忌 贝卡普勒明是一种局部外用凝胶，与其他合适的创伤护理措施相结合，可用来促进面积小于5平方厘米的全厚皮片神经性慢性糖尿病性溃疡的愈合。 欧洲医药产品评估局（EMEA）消息，在对使用Regranex (becaplermin，贝卡普勒明，由Janssen-Cilag公司生产)的患者中可能发生癌症风险的数据进行审查后，欧洲药品管理局(European Medicines Agency)认为该药不应用于已患有任何类型癌症的患者。 尽管之前已发布过类似的用药限制，但仅针对在接近用药部位患有皮肤癌的患者。由于在少数使用Regranex凝胶的患者中已有发生癌症的报告，故欧洲委员会(European Commission)要求进行上述审查，此次审查由欧洲药品管理局下的人用医学产品委员会(CHMP)负责进行。 在一项观察性研究中，将使用Regranex的患者与由未使用该药的患者所组成的对照组进行了比较，在这两组患者之间，在发生癌症的总体风险方面未见明显差异。不过，使用3支或更多Regranex凝胶并且发生过癌症的患者较未使用该药者，死于原有癌症的风险要高。由于该研究在其设计中具有一些限制(包括少数癌症病例)，故考虑不是非常可靠。 CHMP提醒，尽管尚无Regranex与癌症关联的可靠证据，但也无足够的证据排除这种联系。 因此，该委员会得出结论认为，作为一种预防措施，该药不应用于之前已患有癌症的患者。 CHMP还要求生产商提供更多有关该药可能被吸收至患者体内的信息，并进行其他流行病学研究，以收集更多有关Regranex与癌症和癌症结果之间关联的可靠证据。目前，CHMP的建议已被提交至欧洲委员会，以便作为一种具有法律约束力的决定而被采用。 英国医药产品监管局(MHRA) 2010年4月号药物安全通报建议医药专业人士，评估治疗措施，对任何部位患有癌症的病人不开具贝卡普勒明处方。溃疡有可疑症状时应做活检，排除恶性肿瘤。 |
